Australian Doctor 22nd Aug 2025 | Page 34

Fixed dose triple therapy in a pMDI for patients with moderate to very severe COPD

Clinical Focus

22 AUGUST 2025 ausdoc. com. au
AUSDOC’ S TOP FIVE CLINICAL ARTICLES
Case Report

A cold dip concern

1. Spot Dx: Nailing a tricky diagnosis
Page views: 2200
Is immersion in icy water after a walk to blame for this active retiree’ s pain and blotchy rash?
2. Doctors clash over JAMA review of antidepressant withdrawal risks
Page views: 2000
3. Aussie experts back dialectical behaviour therapy for premenstrual dysphoric disorder
Page views: 1900
4. Case Report: Time for a break from bisphosphonates?
Page views: 1700
5. How to Treat: Otitis media in children
Page views: 1500
Source: AusDoc website; 18 Jul to 11 Aug.
Dr Liz Fraser GP in Canberra, ACT.

JEN, aged 67, enjoys an active retirement. A former health professional, she focuses on improving her health as she ages, and is physically active— hiking, gardening and swimming. Jen has a background of Graves’ disease, in remission for 10 years. She is a lifelong non-smoker who takes no medications. She consumes a wholefood low carbohydrate diet. For the past few years, one of her great pleasures is a weekly bushwalk, often combined with a cold water dip during the cooler months.

Jen is perplexed when, five days after a day procedure that required a short general anaesthetic, she develops widespread aches and pains, similar to her previous experiences of post-exercise delayed onset muscle soreness. This is odd as she has not done anything sufficiently vigorous to account for this. There is no associated fever or malaise and Jen initially suspects that the discomfort might be related to the general
anaesthetic or being moved around the theatre while unconscious. However, over the next week, her symptoms progress and she develops a blotchy red plaque-like rash over her breasts, abdomen and thighs( see figure 1). Around day seven post-procedure, she develops what appears to be thrombophlebitis in the greater saphenous veins of both thighs( see figure 2). Alarmed, Jen consults with her GP.
On examination Jen is afebrile, her BP is 115 / 70mmHg and heart rate 62bpm and regular. She weighs 69kg with a BMI of 23. She is afebrile, with extensive erythema and marked red, tender thickening along both greater saphenous veins. An urgent ultrasound shows inflammation in the subcutaneous fat of the thighs. Reassuringly, there is no superficial or deep venous thrombosis.
Jen mentions that a few days after the procedure, she went on a short bushwalk and dipped in water that was around 8 ° C for 10 minutes or so. This is not unusual for Jen. The symptoms developed two days after this, in a distribution consistent with the body parts that were exposed to cold water, and sparing Jen’ s shoulders, neck and head, which were not submerged. The GP and Jen suspect this unusual presentation may be cold panniculitis, which is expected to resolve with time.
Discussion
Skin and subcutaneous adipose tissue have multiple functions, including protection from mechanical injury, insulation

GO FOR the GOLD DEVICE 1

Fixed dose triple therapy in a pMDI for patients with moderate to very severe COPD
SCAN TO ORDER BREZTRI ® SAMPLE
INDICATION: BREZTRI AEROSPHERE ® is indicated as a maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe COPD who require treatment with a combination of ICS, LABA, and LAMA. 1 BREZTRI AEROSPHERE ® is not indicated for the initiation of therapy in COPD. 1 SAFETY: In ETHOS, adverse events that occurred in ≥3 % of patients overall for BREZTRI ® and GLY / FORM were nasopharyngitis, COPD, upper respiratory tract infection, pneumonia and bronchitis. 2 The incidence of confirmed pneumonia was 4.2 % with BREZTRI ® and 2.3 % with GLY / FORM. 1, 2 Please review Product Information for information on other Precautions and Adverse Effects.
PBS Information: Authority required( STREAMLINED) for the treatment of COPD. Refer to PBS for full authority information.
PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING. PRODUCT INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342 OR WWW. ASTRAZENECA. COM. AU / PI OR BY SCANNING THIS QR CODE.
SCAN QR CODE to see full BREZTRI ® Product Information
COPD = chronic obstructive pulmonary disease; FORM = formoterol; GLY = glycopyrronium; ICS = inhaled corticosteroid; LABA = long-acting beta 2 agonist; LAMA = long-acting muscarinic antagonist; pMDI = pressurised Metered Dose Inhaler. References: 1. BREZTRI AEROSPHERE ® Approved Product Information. 2. Rabe F et al. N Engl J Med. 2020; 383( 1): 35 – 48.
BREZTRI ® and AEROSPHERE ® are registered trademarks of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www. astrazeneca. com. au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via https:// contactazmedical. astrazeneca. com. 2743. AU-21580. January 2025.
AU-21580- 2743 BREZTRI Media Placements 2025 _ ADG _ 260mmW x 133mmH _ v1 _ 02-FA. indd 1 23 / 1 / 2025 5:29 pm